Rosati, R., Chen, B., Patki, M., McFall, T., Ou, S., Heath, E., . . . Qin, Z. (2016). Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells. Mol Pharmacol.

Rosati, Rayna, Bailing Chen, Mugdha Patki, Thomas McFall, Siyu Ou, Elisabeth Heath, Manohar Ratnam, and Zhihui Qin. "Hybrid Enzalutamide Derivatives With Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells." Mol Pharmacol 2016.

Rosati, Rayna, et al. "Hybrid Enzalutamide Derivatives With Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells." Mol Pharmacol 2016.